Non-Small Cell Lung Cancer: Optimizing Systemic Therapy Options Beyond the 1st Line
Curriculum:
Non-Small Cell Lung Cancer: Optimizing Systemic Therapy Options Beyond the 1st Line
Non-Small Cell Lung Cancer: Optimizing Systemic Therapy Options Beyond the 1st Line
Credits:
0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
January 30, 2018
January 30, 2018
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
This activity is designed to meet the educational needs of oncologists, oncology nurses, pathologists, radiologists, pharmacists, and other healthcare practitioners who care for patients with lung cancer.
Relevant Terms:
Non-Small Cell Lung Cancer
Mark A. Socinski, MD
Mark A. Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section, Division of Hematology Oncology
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh, UPMC Cancer Pavilion
Pittsburgh, PA
Bio
.jpg)
Mark A. Socinski, M.D. is Professor of Medicine and Thoracic Surgery and Director of the Lung Cancer Section, Division of Hematology/Oncology at the University of Pittsburgh. He also is Co-Director of the UPMC Lung Cancer Center of Excellence and the Lung and Thoracic Malignancies Program and the Clinical Associate Director of the Specialized Program of Research Excellence (SPORE) in Lung Cancer at the University of Pittsburgh Medical Center. He is board certified in internal medicine and medical oncology.Dr. Socinski received his MS in pathology and his MD from the University of Vermont in Burlington. He completed an internal medicine internship and residency at Harvard Medical School Beth Israel Hospital in Boston. He went on to complete medical oncology and clinical medicine fellowships at the Dana-Farber Cancer Institute, Harvard Medical School.
Dr. Socinski is a member of several professional organizations including the American College of Physicians, the American Society of Clinical Oncology, Cancer and Leukemia Group B, the International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He has authored many manuscripts principally in the field of Thoracic Oncology.
| 1. | Describe the use of clinical presentation and biomarker data to guide treatment after progression beyond platinum-based chemotherapy; | 2. | Review clinical trial data from studies of advanced NSCLC in support of subsequent lines of treatment in patients who have progressed through first-line therapy; |
| 3. | Apply the NCCN guidelines for second-line treatment and beyond in patients who have progressed after platinum-based chemotherapy. |
| 1. | Describe the use of clinical presentation and biomarker data to guide treatment after progression beyond platinum-based chemotherapy; |
| 2. | Review clinical trial data from studies of advanced NSCLC in support of subsequent lines of treatment in patients who have progressed through first-line therapy; |
| 3. | Apply the NCCN guidelines for second-line treatment and beyond in patients who have progressed after platinum-based chemotherapy. |
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
UMA/Complete Conference Management is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA. Complete Conference Management will provide this educational activity for 0.5 contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Mark A. Socinski, MD, has nothing to disclose.
CME content review
Mark A. Socinski, MD, has nothing to disclose.
CME content review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer, and the reviewer of this activity has nothing to disclose.
Planning Committee
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Nina Oshiokpekhai, MS, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Nina Oshiokpekhai, MS, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
TO OBTAIN CME CREDITS:
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the post-test and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• You must score 70% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the post-test and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• You must score 70% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
Copyright © 2017 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
This activity is provided by Med Learning Group.
This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grant by Lilly.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
